Liver function may change how this drug works – early study begins

NCT ID NCT07269301

Recruiting now Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This early-stage study by Pfizer looks at how different levels of liver function affect the processing of a new drug called PF-07328948. About 26 adults with and without liver impairment will take a single tablet and stay at the clinic for 6 days for monitoring and blood tests. The goal is to see if liver problems change how the drug moves through the body, which could guide future dosing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PF-07328948 (a drug taken as a tablet)
What this could lead to: If successful, this study could help determine safe dosing of PF-07328948 for people with liver problems.
What could go wrong: This is a very early Phase 1 trial with only 26 participants, so results may not apply broadly. The drug may still fail in later studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY HEPATIC IMPAIRMENT

Contacts and locations

Locations

Genesis Clinical Research, LLC
RECRUITING

Tampa, Florida, 33603, United States
Orange County Research Center
RECRUITING

Lake Forest, California, 92630, United States
Orlando Clinical Research Center
RECRUITING

Orlando, Florida, 32809, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.